RSS

Medherant

A developer of transdermal drug delivery treatments for pain and central nervous systems diseases has been awarded a Medicines Manufacturing Grant by Innovate UK. Read more

News

Medherant’s Sukhy Nandra, Vasiliki Nikolaou and David Haddleton discuss the benefits and limitations of transdermal drug delivery systems. Read more

, , Opinion

Drug delivery company Medherant has announced that it has successfully completed two Phase I studies focusing on its Ibuprofen TEPI Patch. Read more

News

European Pharmaceutical Manufacturer editor, Felicity Thomas, sits down with Sally Waterman, COO at Medherant to discuss the benefits of transdermal drug delivery and how industry developments and changes in patient needs are leading to a shift… Read more

, Opinion

Here, we talk with David Davies, whose appointment as the new head of development at Medherant marks the company’s move into clinical development of the ibuprofen TEPI Patch. Read more

Opinion

Medherant — a company focused on transdermal drug delivery — has revealed that it has raised £3.8 million in its latest funding round, which will support the company as it progresses its ibuprofen TEPI Patch into clinical development early next year Read more

News

Medherant, developer of transdermal drug delivery patches, has been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards. Read more

Technology

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Developer of next-generation transdermal drug delivery patches, Medherant, has signed an agreement with a Japanese transdermal patch company to evaluate the potential of the TEPI Patch technology. Read more

Technology

In this article Vasiliki Nikolaou and David M. Haddleton from Medherant, The Venture Centre University of Warwick Science Park, detail transdermal drug delivery, a non-invasive option that has the potential to improve patient adherence. Read more

, Opinion

University of Warwick spin-out company that is developing a transdermal drug delivery patch technology, Medherant, has been shortlisted for the Royal Society of Chemistry (RSC) Emerging Technologies Competition 2017. Read more

News

Medherant, a University of Warwick spin-out company, developing transdermal drug delivery patch technology, has announced the appointment of Sheryl Caswell as head of clinical development. Read more

News

University of Warwick spin-out company, Medherant, has appointed Laboratoires Plasto Santé to manufacture its drug delivery patches, which will be based on novel transdermal drug delivery technology. Read more

News

Researchers at the University of Warwick have worked with Medherant, a Warwick spinout company, to produce and patent the first ibuprofen patch that delivers the drug directly through skin at a consistent dose rate Read more

News